The website restofworld got entries from 45 countries for a photo contest focusing on technology. Here are their top picks -- ...
In the interconnected ASX healthcare sector it can be common for leaders to be involved in multiple companies and ...
Discover the latest developments in potential ALS treatments with COYA-302 and COYA-303, set to impact the $1.33 billion ...
At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of ...
Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...
Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life.
(HT) “We were working on sensor technology and I was the person with the biotech background. There were reports about the sense of smell that dogs possess and how it was possible for them to ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback